Company Profile

Acell Inc
Profile last edited on: 4/2/21      CAGE:       UEI:

Business Identifier: Regenerative medicine products: facilitates body's ability to remodel functional tissue
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

8671 Robert Fulton Drive Suite B
Columbia, MD 21046
   (410) 715-1700
Location: Multiple
Congr. District: 03
County: Howard

Public Profile

In December 2020, ACell was acquired by Integra LifeSciences, an integrated medical device company itself having been - albeit briefly - an SBIR funded firm. Previously located in Massachusetts, ACell Inc. is a regenerative medicine company developing tissue-engineered products that encourage the body's own response system to help repair damaged tissue. Fairly active in SBIR in its early years, ACell has been focused to expanding its position in the veterinary care field. Based on naturally occurring biological scaffolds, the tissue-engineered products produced by ACell change the fundamental healing response by encouraging the body’s own regenerative capabilities to repair tissues and restore them to natural health. The company’s technology increases the breadth of treatment options for disease and injuries and has applicability in a wide variety of treatments including wound care, surgery, orthopedics, dermatology, and cardiovascular medicine. ACell markets, distributes, and sells its products both directly and through strategic partner

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 1 NIH $102,950
Project Title: ECM Bioscaffold for ASD Repair
2004 1 NIH $100,000
Project Title: Three Dimensional ECM Scaffolds for Tissue Engineering
2004 2 NIH $883,924
Project Title: A Biomaterial For Esophageal Repair
2002 2 NIH $850,000
Project Title: Tissue Engineered Heart Valve
2001 1 NIH $110,000
Project Title: A Device For Repair Of Mucogingival Tissue

Key People / Management

  James DeFrancesco -- President

  Alan R Spievack -- Founder and Director of Technology

Company News

There are no news available.